Strattera (atomoxetine) and Wellbutrin (bupropion) are sometimes compared for ADHD, but only Strattera actually carries an FDA approval for that use — Wellbutrin is approved for depression, and any ADHD use is off-label. This guide explains what that distinction means in practice, plus mechanism, dosing, and side effect differences between the two.
This is general information, not medical advice.
Strattera vs Wellbutrin at a glance
| Strattera (atomoxetine) | Wellbutrin (bupropion) | |
|---|---|---|
| FDA-approved for ADHD | Yes | No (off-label use only) |
| FDA-approved for | ADHD | Depression (major depressive disorder, seasonal affective disorder as Wellbutrin XL) |
| Drug class | Selective norepinephrine reuptake inhibitor | Norepinephrine-dopamine reuptake inhibitor (atypical antidepressant) |
| Controlled substance | No | No |
| Boxed warning | Suicidal ideation in children/adolescents | Suicidal thoughts and behaviors (antidepressant class warning) |
| Generic available | Yes | Yes |
The most important distinction: only one is approved for ADHD
This is the detail that matters most in this comparison. Strattera is FDA-approved specifically for ADHD. Wellbutrin is FDA-approved for major depressive disorder (and, as Wellbutrin XL, for seasonal affective disorder prevention); its use for ADHD symptoms is off-label, meaning a doctor can still prescribe it for that purpose based on clinical judgment and supporting research, but it hasn’t gone through FDA review specifically for ADHD the way Strattera has.
Off-label use is common and legal in medicine, and some research does support bupropion’s effectiveness for ADHD symptoms, but patients should understand the difference between an approved indication (backed by an FDA-reviewed trial program specific to that use) and an off-label one (backed by a mix of smaller studies, clinical experience, and extrapolation from the drug’s known mechanism) before deciding which framing matters to them.
How they work
Strattera (atomoxetine) is a selective norepinephrine reuptake inhibitor: it mainly blocks the reuptake of norepinephrine, a mechanism directly tied to ADHD’s presumed underlying neurochemistry.
Wellbutrin (bupropion) is a norepinephrine-dopamine reuptake inhibitor, affecting both norepinephrine and dopamine. Its dopaminergic activity is part of why researchers have investigated it for ADHD, since dopamine signaling is also implicated in ADHD, alongside its established role as an antidepressant. A review of bupropion for ADHD noted a delayed onset of action in adults, a pattern similar to Strattera’s own gradual-onset profile rather than the fast effect of stimulants.
Dosing
Strattera dosing is weight-based in patients under 70 kg, generally titrated over 2 to 4 weeks to a target dose, dosed once or twice daily.
Wellbutrin for depression is typically dosed based on the specific formulation (immediate-release, SR, or XL), usually once or twice daily depending on the version; when used off-label for ADHD, dosing follows similar general ranges to its depression dosing, adjusted by the prescriber based on response, since there is no FDA-established ADHD-specific dosing schedule to follow.
Side effects
Both carry a boxed warning related to suicidal thoughts and behavior, though the framing differs: Strattera’s is specific to increased suicidal ideation risk in children and adolescents based on ADHD trial data; Wellbutrin’s reflects the broader antidepressant-class warning applied to all antidepressants regarding suicidality risk in children, adolescents, and young adults.
Strattera’s more specific additional warnings include severe liver injury (requiring discontinuation if signs appear) and cardiovascular events. Wellbutrin carries its own specific warning regarding seizure risk, which is dose-dependent and a reason why the maximum recommended dose and dosing schedule (avoiding large single doses) are followed carefully; this seizure risk is a consideration unique to bupropion among the ADHD-adjacent drugs discussed on this site, not something Strattera’s label carries.
Common side effects overlap somewhat: both can cause dry mouth, nausea, and insomnia or sleep disruption. Wellbutrin is also associated with decreased appetite and, notably, is sometimes chosen partly because it is less likely than many other antidepressants to cause sexual side effects or significant weight gain, which is part of its broader reputation in psychiatric practice, separate from its ADHD use specifically.
Who each might suit
Factors that may point toward Strattera:
- Wanting an FDA-approved-for-ADHD option specifically, with a trial program and label backing that use directly
- No co-occurring depression requiring separate antidepressant treatment
- A seizure history, where Wellbutrin’s dose-dependent seizure risk would be a specific concern to avoid
Factors that may point toward Wellbutrin (as an off-label option, decided with a prescriber):
- Co-occurring depression, where one medication addressing both conditions may be preferred over adding a second drug
- A prior negative reaction to Strattera specifically, such as liver-related concerns
- A prescriber’s clinical judgment that the dopaminergic mechanism may suit a specific patient’s symptom pattern better, informed by the off-label research base
Frequently asked questions
Is Wellbutrin FDA-approved for ADHD?
No. It’s approved for depression; any ADHD use is off-label, based on smaller studies and clinical judgment rather than an FDA-reviewed ADHD-specific trial program.
Which works faster for ADHD, Strattera or Wellbutrin?
Neither works as fast as a stimulant. Research on bupropion for ADHD has noted a delayed onset of action in adults, similar in pattern to Strattera’s own gradual buildup over weeks.
Can Wellbutrin cause seizures?
It carries a specific, dose-dependent seizure risk warning, which is why dosing schedules avoid large single doses. This is a warning unique to bupropion among the drugs compared on this site, not something Strattera’s label carries.
Is Wellbutrin a controlled substance?
No, neither Wellbutrin nor Strattera is a controlled substance.
Can someone with both depression and ADHD use Wellbutrin for both?
Some prescribers do consider bupropion for patients with both conditions, given its off-label ADHD use and approved depression indication, but this decision should be made individually with a prescriber weighing the off-label evidence against approved alternatives.
What the off-label research actually shows
Off-label doesn’t mean unstudied. Multiple smaller randomized controlled trials have evaluated bupropion for adult ADHD, and a Cochrane-style systematic review found evidence suggesting some benefit over placebo for ADHD symptoms, alongside noting the delayed onset of action typical of the drug and highlighting that study quality and sizes have generally been more modest than the larger trial programs that supported Strattera’s original FDA approval specifically for ADHD. This is the core reason the two occupy different regulatory positions despite both being considered by clinicians for the same condition: the strength and specificity of the evidence base each has been reviewed against differs.
Why a prescriber might reach for an off-label option at all
Off-label prescribing is a normal, legal part of medicine, and it happens for several practical reasons: a patient has already tried and not tolerated the FDA-approved options; a co-occurring condition (like depression, in Wellbutrin’s case) makes a dual-purpose medication attractive; the specific mechanism of the off-label drug seems better suited to a patient’s particular symptom pattern based on clinical experience; or cost and insurance coverage make an already-approved-for-something-else generic more accessible than a newer, ADHD-specific option. None of these reasons make off-label use inherently riskier by default, but they do mean the decision rests more heavily on the individual prescriber’s judgment and the existing (often smaller) research base rather than an FDA-reviewed trial program built specifically around that use.
Combining the two
Because bupropion and atomoxetine work through different mechanisms and are approved for different primary conditions, they are sometimes used together, for example when a patient has both depression and ADHD symptoms not fully controlled by one drug alone, though this combination should be managed carefully by a prescriber given the seizure risk consideration with bupropion and the need to monitor for medication interactions and additive side effects.
Frequently asked questions (continued)
Does research actually support Wellbutrin for ADHD?
Some smaller randomized trials and systematic reviews have found evidence of benefit, though generally with more modest study sizes and quality than the trial program that specifically supported Strattera’s FDA approval for ADHD.
Why would a doctor prescribe an off-label drug instead of an approved one?
Common reasons include prior intolerance to approved options, a co-occurring condition the off-label drug also treats, a mechanism thought to suit the individual patient, or cost and access considerations. It’s a normal, legal part of clinical practice.
Can Strattera and Wellbutrin be combined?
Sometimes, particularly for patients with both depression and ADHD, but this should be managed carefully by a prescriber given bupropion’s seizure risk and the need to watch for interactions.